Hemogenix®
Contract research organization providing in vitro, cell-based toxicology and cell biology services. Core offerings include standardized, validated high-throughput plate-based cytotoxicity screening using ATP bioluminescence readouts, primary and iPS/ES-derived cell systems, flow cytometry and multiplex cytokine measurement. Services cover multi-tissue comparative screening, mechanism-of-action and drug-drug interaction studies, potency and quality testing for cellular therapy products, GLP or non-GLP study workflows, and distribution/facilitation of third-party assay kits for in-house use.
Industries
Nr. of Employees
small (1-50)
Products
Standardized high-throughput ATP-based toxicity assay platforms
Plate-based ATP bioluminescence platforms for tissue-specific toxicity testing available as contract services or via third-party assay kits for in-house use.
Assay kits and 'assays-in-a-box' for in-house use
Third-party assay kits that replicate contract laboratory platforms for toxicity, potency and quality testing; include reagents, controls and standardized protocols (cells not included).
Standardized high-throughput ATP-based toxicity assay platforms
Plate-based ATP bioluminescence platforms for tissue-specific toxicity testing available as contract services or via third-party assay kits for in-house use.
Assay kits and 'assays-in-a-box' for in-house use
Third-party assay kits that replicate contract laboratory platforms for toxicity, potency and quality testing; include reagents, controls and standardized protocols (cells not included).
Services
Customized, QA-audited studies including study plan, draft and final reports, raw data and regulatory-use documentation suitable for IND submissions.
Streamlined workflows for early-stage screening delivering study plan, protocol, raw results and graphical data in standardized electronic workbooks without formal text interpretation or QA audit.
Set-price multi-tissue panels to compare toxicity across tissues and rank compounds using standardized readouts.
Cellular-level MOA studies and combination/DDI cross-titration studies across tissues with CYP450 enzyme assays and mechanistic add-ons.
Procurement, mononuclear cell fractionation, expansion and quality assessment of primary human and animal cells for use in toxicity and potency assays.
Design and validation of quantitative potency assays for hematopoietic, mesenchymal and pluripotent cell products, GLP-capable testing and issuance of certificates of potency for sample release.
Customized, QA-audited studies including study plan, draft and final reports, raw data and regulatory-use documentation suitable for IND submissions.
Streamlined workflows for early-stage screening delivering study plan, protocol, raw results and graphical data in standardized electronic workbooks without formal text interpretation or QA audit.
Set-price multi-tissue panels to compare toxicity across tissues and rank compounds using standardized readouts.
Cellular-level MOA studies and combination/DDI cross-titration studies across tissues with CYP450 enzyme assays and mechanistic add-ons.
Procurement, mononuclear cell fractionation, expansion and quality assessment of primary human and animal cells for use in toxicity and potency assays.
Design and validation of quantitative potency assays for hematopoietic, mesenchymal and pluripotent cell products, GLP-capable testing and issuance of certificates of potency for sample release.
Expertise Areas
- In vitro toxicology screening and testing
- High-throughput plate-based ADME/Tox screening
- Hematopoietic stem and progenitor functional testing
- Immunotoxicity and immune-function assays
Key Technologies
- ATP bioluminescence viability assays
- High-throughput 96/384-well plate screening
- Automated liquid handling and plate reader integration
- Plate-based multicolor flow cytometry
News & Updates
Received National Cancer Institute SBIR grant support (Phase I/II) to develop a high-throughput hematotoxicity screening platform in the early 2000s.
Platform validated against a registry of cytotoxicity prediction models and reported high in vitro-to-in vivo concordance (~80%+ in cited analyses).
Study results produced by the company's assay platforms have been included in IND application materials to regulatory authorities.
Received National Cancer Institute SBIR grant support (Phase I/II) to develop a high-throughput hematotoxicity screening platform in the early 2000s.
Platform validated against a registry of cytotoxicity prediction models and reported high in vitro-to-in vivo concordance (~80%+ in cited analyses).
Study results produced by the company's assay platforms have been included in IND application materials to regulatory authorities.